183 related articles for article (PubMed ID: 16890733)
1. Phosphodiesterase-5 isoforms: differential cyclic guanyl monophosphate binding and cyclic guanyl monophosphate catalytic activities, and inhibitory effects of sildenafil and vardenafil.
Lin G; Xin ZC; Lue TF; Lin CS
J Urol; 2006 Sep; 176(3):1242-7. PubMed ID: 16890733
[TBL] [Abstract][Full Text] [Related]
2. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
3. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
Zoraghi R; Corbin JD; Francis SH
J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
[TBL] [Abstract][Full Text] [Related]
6. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
Sarfati M; Mateo V; Baudet S; Rubio M; Fernandez C; Davi F; Binet JL; Delic J; Merle-Beral H
Blood; 2003 Jan; 101(1):265-9. PubMed ID: 12393651
[TBL] [Abstract][Full Text] [Related]
8. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
9. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat.
Prickaerts J; van Staveren WC; Sik A; Markerink-van Ittersum M; Niewöhner U; van der Staay FJ; Blokland A; de Vente J
Neuroscience; 2002; 113(2):351-61. PubMed ID: 12127092
[TBL] [Abstract][Full Text] [Related]
10. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
McCullough A
Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
[TBL] [Abstract][Full Text] [Related]
14. Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
Wang H; Ye M; Robinson H; Francis SH; Ke H
Mol Pharmacol; 2008 Jan; 73(1):104-10. PubMed ID: 17959709
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
16. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Kloner RA
Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
[No Abstract] [Full Text] [Related]
18. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.
Bessay EP; Zoraghi R; Blount MA; Grimes KA; Beasley A; Francis SH; Corbin JD
Front Biosci; 2007 Jan; 12():1899-910. PubMed ID: 17127429
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
20. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
Corbin JD; Beasley A; Blount MA; Francis SH
Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]